Spero Therapeutics, Inc. (NASDAQ:SPRO) Short Interest Update

Spero Therapeutics, Inc. (NASDAQ:SPRO) saw a significant decline in short interest in April. As of April 15th, there was short interest totalling 513,200 shares, a decline of 21.5% from the March 31st total of 653,800 shares. Based on an average daily volume of 321,500 shares, the short-interest ratio is presently 1.6 days.

Spero Therapeutics Stock Performance

SPRO traded up $0.03 on Friday, hitting $1.46. 165,357 shares of the company were exchanged, compared to its average volume of 219,213. Spero Therapeutics has a 12 month low of $0.99 and a 12 month high of $2.00. The company has a market cap of $78.68 million, a PE ratio of 3.48 and a beta of 0.55. The stock’s fifty day moving average is $1.63 and its 200-day moving average is $1.42.

Spero Therapeutics (NASDAQ:SPRO) last released its earnings results on Wednesday, March 13th. The company reported $0.96 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $1.14. Spero Therapeutics had a return on equity of 38.54% and a net margin of 21.98%. The business had revenue of $73.52 million for the quarter, compared to analyst estimates of $19.40 million. As a group, equities research analysts expect that Spero Therapeutics will post -0.94 EPS for the current fiscal year.

Institutional Trading of Spero Therapeutics

An institutional investor recently raised its position in Spero Therapeutics stock. Acadian Asset Management LLC raised its holdings in Spero Therapeutics, Inc. (NASDAQ:SPRO) by 56.8% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 272,024 shares of the company’s stock after buying an additional 98,485 shares during the period. Acadian Asset Management LLC owned about 0.52% of Spero Therapeutics worth $327,000 at the end of the most recent quarter. Institutional investors own 25.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on SPRO. Cantor Fitzgerald restated an “overweight” rating on shares of Spero Therapeutics in a report on Thursday, April 4th. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Spero Therapeutics in a report on Monday, March 18th.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.